Nebilet (Nebivolol)

Nebivolol, the active ingredient in Nebilet, is a beta blocker presented as an oral tablet for oral use. It is used to treat hypertension and heart failure in adult patients. GNH USA supplies Nebilet as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nebilet is a selective β1‑adrenergic blocker indicated for cardiovascular conditions that require blood pressure control or improved cardiac function. - Hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk. - Heart failure (reduced ejection fraction): improves ventricular performance and decreases hospitalization. - Left ventricular systolic dysfunction: enhances myocardial relaxation and supports cardiac output.

Nebilet may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Headache: mild to moderate discomfort. - Dizziness or light‑headedness: especially on standing. - Fatigue: feeling unusually tired. - Bradycardia: slower than normal heart rate. - Nausea: upset stomach. - Peripheral edema: swelling of ankles or feet.

Serious or Rare Side Effects: - Severe bradycardia or heart block: may require medical attention. - Marked hypotension: sudden drop in blood pressure. - Bronchospasm: difficulty breathing, particularly in asthmatic patients. - Allergic reactions: rash, itching, or swelling. - Hepatic dysfunction: abnormal liver enzymes. - Acute heart failure exacerbation: worsening symptoms of heart failure.

Before starting Nebilet, several safety considerations should be reviewed. - Blood pressure monitoring: ensure adequate control and avoid excessive drops. - Cardiac function assessment: evaluate for existing bradyarrhythmias or heart block. - Asthma or chronic obstructive pulmonary disease: use with caution due to potential bronchospasm. - Concomitant beta‑blockers: avoid duplication to prevent excessive β‑blockade. - Renal or hepatic impairment: dose may need adjustment. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Nebilet can interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Other β‑blockers: additive cardiac depression. - Non‑dihydropyridine calcium channel blockers (verapamil, diltiazem): risk of severe bradycardia or AV block. - Clonidine abrupt discontinuation: may cause rebound hypertension. - Potent CYP2D6 inhibitors (paroxetine, fluoxetine): increase nebivolol plasma levels. - Anti‑arrhythmic agents (class IA/III): heightened risk of conduction disturbances.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: may enhance hypotensive effect. - Diuretics: potential for electrolyte imbalance and excessive blood pressure fall. - NSAIDs: may attenuate antihypertensive response. - Digoxin: monitor for bradycardia. - Alcohol: can increase dizziness and hypotension.